Mode
Text Size
Log in / Sign up
N/A N=27

Erythrocyte and Adipocyte G6PD Activity Levels in Obesity

Diabetes · Obesity

Enrolled (actual)
27
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of South Alabama
Primary completion
Mar 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass.
3.12; 0.67; 22; 13; 20; 12 <0.05 sig
SECONDARY
Measure Adipocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass.
3.12; 0.67; 22.1; 13; 21.9; 12.5
SECONDARY
Measure Omentum G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass.
13; 12
SECONDARY
Measure Hepatocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass.
17; 11.9

Summary

This study compares the improvement of weight, fasting lipid profile (triglycerides, cholesterol, HDL, and LDL) and diabetes after gastric bypass surgery with an improvement in levels of an enzyme called glucose-6-phosphate dehydrogenase (G6PD).

Eligibility Criteria

Inclusion Criteria

  • Age > 19 years of age and <70 years of age
  • HGA1c<6.0%
  • fasting blood sugar less than 100mg/dL

Exclusion Criteria

  • Taking antidiabetic medications for other indications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01322035). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search